{"transactions":[{"id":703530,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-24T21:57:57.000Z","date":"2026-07-23","kind":"sale","planned":false,"acquired":false,"shares":6798,"price":38.69,"value":263014.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 1, 2025, the holder was granted 208,388 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on May 5, 2025, of which 13,024 of these RSUs vested on July 21, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 - $39.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":240798,"source":{"system":"sec-edgar","filing":"0001618670-26-000004","document":"wk-form4_1784930275.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000161867026000004/wk-form4_1784930275.xml","form_type":"4"}},{"id":725541,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T23:44:00.000Z","date":"2026-06-26","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a grant date of May 1, 2025. The shares underlying the option vest as to 25% on April 21, 2026, with the remainder vesting in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date."}],"balance_after":283505,"derivative":{"exercise_price":15.9,"expiration_date":"2035-05-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001764013-26-000072","document":"wk-form4_1782517438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000072/wk-form4_1782517438.xml","form_type":"4"}},{"id":725540,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:44:00.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":38.46,"value":384600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 - $38.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":247596,"source":{"system":"sec-edgar","filing":"0001764013-26-000072","document":"wk-form4_1782517438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000072/wk-form4_1782517438.xml","form_type":"4"}},{"id":725539,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:44:00.000Z","date":"2026-06-26","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":15.9,"value":159000.0,"ownership":{"direct":true},"balance_after":257596,"source":{"system":"sec-edgar","filing":"0001764013-26-000072","document":"wk-form4_1782517438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000072/wk-form4_1782517438.xml","form_type":"4"}},{"id":801000,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-24T20:07:14.000Z","date":"2026-04-23","kind":"sale","planned":false,"acquired":false,"shares":25760,"price":29.62,"value":763011.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 1, 2025, the holder was granted 208,388 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on May 5, 2025, of which 52,097 of these RSUs vested on April 21, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.23 - $30.00 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":247596,"source":{"system":"sec-edgar","filing":"0001764013-26-000056","document":"wk-form4_1777061232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000056/wk-form4_1777061232.xml","form_type":"4"}},{"id":811512,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:10:31.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":94002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":94002,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":94002},"source":{"system":"sec-edgar","filing":"0001764013-26-000032","document":"wk-form4_1775765429.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000032/wk-form4_1775765429.xml","form_type":"4"}},{"id":811511,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-09T20:10:31.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":64968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":273356,"source":{"system":"sec-edgar","filing":"0001764013-26-000032","document":"wk-form4_1775765429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000032/wk-form4_1775765429.xml","form_type":"4"}},{"id":1159363,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-05T23:30:09.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":293505,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 21, 2026 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":293505,"derivative":{"exercise_price":15.9,"expiration_date":"2035-05-01","underlying":"Common Stock","underlying_shares":293505},"source":{"system":"sec-edgar","filing":"0001415889-25-012047","document":"form4-05052025_070505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000141588925012047/form4-05052025_070505.xml","form_type":"4"}},{"id":1159362,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-05T23:30:09.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":208388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 21, 2026 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":208388,"source":{"system":"sec-edgar","filing":"0001415889-25-012047","document":"form4-05052025_070505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000141588925012047/form4-05052025_070505.xml","form_type":"4"}},{"id":1503227,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-23T21:45:32.000Z","date":"2024-05-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger (\"Effective Time\"), this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger (\"Effective Time\"), this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger (\"Effective Time\"), this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":9.1,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001415889-24-014341","document":"form4-05232024_050515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1618670/000141588924014341/form4-05232024_050515.xml","form_type":"4"}},{"id":1503226,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-23T21:45:32.000Z","date":"2024-05-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger (\"Effective Time\"), this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger (\"Effective Time\"), this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger (\"Effective Time\"), this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":6.4,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001415889-24-014341","document":"form4-05232024_050515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1618670/000141588924014341/form4-05232024_050515.xml","form_type":"4"}},{"id":1503225,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-23T21:45:32.000Z","date":"2024-05-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger (\"Effective Time\"), this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger (\"Effective Time\"), this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger (\"Effective Time\"), this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.3,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001415889-24-014341","document":"form4-05232024_050515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618670/000141588924014341/form4-05232024_050515.xml","form_type":"4"}},{"id":1879391,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-24T21:55:35.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable on May 23, 2024, subject to the Reporting Person providing continuous service through such date."}],"balance_after":18000,"derivative":{"exercise_price":0.33,"expiration_date":"2033-05-22","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-23-031945","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618670/000120919123031945/doc4.xml","form_type":"4"}},{"id":2237246,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-09T12:53:06.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable on June 7, 2023, subject to the Reporting Person providing continuous service through such date."}],"balance_after":18000,"derivative":{"exercise_price":0.9145,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-035284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618670/000120919122035284/doc4.xml","form_type":"4"}},{"id":2265154,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-18T20:29:16.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to this option will vest and become exercisable in equal monthly installments commencing May 19, 2022, subject to the Reporting Person providing continuous service to the Issuer."}],"balance_after":18000,"derivative":{"exercise_price":0.6434,"expiration_date":"2032-05-15","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-030046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618670/000120919122030046/doc4.xml","form_type":"4"}},{"id":2751069,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-12T22:01:00.000Z","date":"2021-04-08","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments beginning on April 8, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":36000,"derivative":{"exercise_price":10.16,"expiration_date":"2031-04-07","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-21-026381","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618670/000120919121026381/doc4.xml","form_type":"4"}},{"id":3860217,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP & Chief Financial Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2018-07-27T20:31:45.000Z","date":"2018-07-25","kind":"other","acquired":true,"shares":1050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units (\"Units\"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.7986 through January 25, 2021."}],"balance_after":1050,"derivative":{"exercise_price":0.7986,"expiration_date":"2021-01-25","underlying":"Common Stock","underlying_shares":1050},"source":{"system":"sec-edgar","filing":"0001209191-18-044206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919118044206/doc4.xml","form_type":"4"}},{"id":3860216,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP & Chief Financial Officer"}}],"security":"Series C Preferred Stock","published_at":"2018-07-27T20:31:45.000Z","date":"2018-07-25","kind":"other","acquired":true,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units (\"Units\"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series C Preferred Stock has no expiration date."}],"balance_after":1,"derivative":{"exercise_price":0.7986,"exercise_date":"2018-07-25","underlying":"Common Stock","underlying_shares":1253},"source":{"system":"sec-edgar","filing":"0001209191-18-044206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919118044206/doc4.xml","form_type":"4"}},{"id":3860215,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP & Chief Financial Officer"}}],"security":"Subscription Rights (Right to Buy)","published_at":"2018-07-27T20:31:45.000Z","date":"2018-07-25","kind":"other","acquired":false,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units (\"Units\"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units (\"Units\"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units (\"Units\"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000."}],"balance_after":0,"derivative":{"exercise_price":1000,"exercise_date":"2018-06-29","expiration_date":"2018-07-20","underlying":"See Footnote"},"source":{"system":"sec-edgar","filing":"0001209191-18-044206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919118044206/doc4.xml","form_type":"4"}},{"id":4149402,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP & Chief Financial Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2017-11-29T22:33:50.000Z","date":"2017-11-28","kind":"other","acquired":true,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020."}],"balance_after":1800,"derivative":{"exercise_price":0.3333,"expiration_date":"2020-05-28","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001209191-17-062896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062896/doc4.xml","form_type":"4"}},{"id":4149401,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP & Chief Financial Officer"}}],"security":"Series B Preferred Stock","published_at":"2017-11-29T22:33:50.000Z","date":"2017-11-28","kind":"other","acquired":true,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date."}],"balance_after":1,"derivative":{"exercise_price":0.3333,"exercise_date":"2017-11-28","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-17-062896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062896/doc4.xml","form_type":"4"}},{"id":4149400,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP & Chief Financial Officer"}}],"security":"Subscription Rights (Right to Buy)","published_at":"2017-11-29T22:33:50.000Z","date":"2017-11-28","kind":"other","acquired":false,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."}],"balance_after":0,"derivative":{"exercise_price":1000,"exercise_date":"2017-11-02","expiration_date":"2017-11-21","underlying":"see footnote"},"source":{"system":"sec-edgar","filing":"0001209191-17-062896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062896/doc4.xml","form_type":"4"}},{"id":4380683,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP & Chief Financial Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2017-03-17T21:06:21.000Z","date":"2017-03-08","kind":"grant","acquired":true,"shares":31100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments."}],"balance_after":31100,"derivative":{"exercise_price":1.55,"expiration_date":"2027-03-08","underlying":"Common Stock","underlying_shares":31100},"source":{"system":"sec-edgar","filing":"0001209191-17-021447","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117021447/doc4a.xml","form_type":"4/A","original_submission_date":"2017-03-10"}},{"id":4391152,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP & Chief Financial Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2017-03-10T22:55:39.000Z","date":"2017-03-08","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments."}],"balance_after":42000,"derivative":{"exercise_price":1.55,"expiration_date":"2027-03-08","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001209191-17-019937","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117019937/doc4.xml","form_type":"4"}}]}